Mireca Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $989K

  • Investors
  • 3

Mireca General Information

Description

Developer of cyclic guanosine monophosphate analog drug products designed for patients suffering from rare and inherited retinal degeneration. The company's drug combines a cyclic guanosine monophosphate analog and drug delivery system to treat broadband photoreceptor mutations, enabling doctors to cure diseases like retinitis pigmentosa, Leber's congenital amaurosis, and Stargardt's disease.

Contact Information

Website
www.mireca.eu
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Paul-Ehrlich-Strasse 5
  • 72076 Tubingen
  • Germany
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Paul-Ehrlich-Strasse 5
  • 72076 Tubingen
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mireca Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 29-Jan-2024 $989K Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 14-Mar-2018 Cancelled Pre-Clinical Trials
2. Early Stage VC 01-Jan-2017 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2017 Completed Pre-Clinical Trials
To view Mireca’s complete valuation and funding history, request access »

Mireca Patents

  • 29

    Total Documents Applications and Grants

  • Total Patents Families

  • 14

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

Mireca Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4598580-A1 Conjugates for neuroretinal drug delivery Pending 06-Oct-2022
US-20260115312-A1 Conjugates for neuroretinal drug delivery Pending 06-Oct-2022
WO-2024074666-A1 Conjugates for neuroretinal drug delivery Inactive 06-Oct-2022
AU-2023355823-A1 Microparticle and implant formulations for cgmp analog therapy Pending 05-Oct-2022
EP-4598504-A2 Microparticle and implant formulations for cgmp analog therapy Pending 05-Oct-2022 A61K9/1647
To view Mireca’s complete patent history, request access »

Mireca Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mireca Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Retinal Degeneration Fund Not-For-Profit Venture Capital
LU Ventures (Lund) Corporate Venture Capital Minority
University of Tübingen University
To view Mireca’s complete investors history, request access »

Ready to get started?

Request a free trial

Mireca FAQs

  • When was Mireca founded?

    Mireca was founded in 2017.

  • Where is Mireca headquartered?

    Mireca is headquartered in Tubingen, Germany.

  • What is the size of Mireca?

    Mireca has 4 total employees.

  • What industry is Mireca in?

    Mireca’s primary industry is Drug Discovery.

  • Is Mireca a private or public company?

    Mireca is a Private company.

  • What is Mireca’s current revenue?

    The current revenue for Mireca is .

  • Who are Mireca’s investors?

    Retinal Degeneration Fund, LU Ventures (Lund), and University of Tübingen have invested in Mireca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process